小児がん経験者の認知機能に関する検討 by 秋山 康介
、





Neurocognitive evaluation of Japanese childhood cancer survivors 
Short running title: Neurocognition in childhood cancer survivors 
｛ 
Kosuke Akiyama1，》白， SatoruIkezawa2，おID,PhD, Yumi Has巴gawa2,PhD,
Yumiko Sugisita 1,:MD, Ryota Kaneko1, :MD, Naoko Okamoto1, :MD, PhD, 
Masaya Koganesawa1, :MD, PhD, Sachio 刊 i旬1,:MD,Ryosuke Matsuno1, J¥⑪， 
PhD, Daisuke Toyama 1,J¥狙コ， PhD,I五rok昭 uIkeda1, J¥狙）， PhD, Shohei 
Yamamoto1,:MD, PhD 
1 Depar仕nentof Pediatrics, Showa U凶versityFu igaoka Hospital, Kanagawa, 
Japan 
《 2National Center of Neurology and Psychia町，To匂ro,Japan 
Correspondence should be addressed to: Kosuke Akiyama, Depar位nentof
Pediatrics, 






TEL.: +81 45 9711151; FAX: +81 45 972 7601 
E-mail: k.akivama@med油 owa-u.ac.io 
Number of text pages: 17 
Number of words: 1353 
Reference pages: 5 
Tables: 2 
Figures: 4 






Long-term cognitive effects following acute lymphoblastic leukemia回 a加 ent
have been reported for Caucasians; however, these data remain unclear for other 
ethnicities and the trea位ientof other cancers. Here, we assessed cognitive 
白nctionin Japanes巴childhoodcancer survivors. 
Methods 
This study enrolled 53 Japanese survivors of childhood cancer (mean age, 9.5 
years; 36 boys and 17 girls). We evaluated performance-based co斜tive
function using the Wechsler Intelligence Scale for Children-Four血Edition
(WISC-IV). Deviation intelligence quotientsσQ) for verbal comprehension 
(VC), percep旬alreasoning (PR), processing speed σS), and working memory 
(WM) were compared withぬ巴standardizedme阻 andstandard deviation (SD; 
《 100制 15,respectively). We classified patients into three groups depending on 
the cumulative methotrexate (MTX) dose (none, 1-19 g/m2, and> 20 g/m2). 
Results 
Full-scale IQ was within normal range at 104.8 (SD, 12.9), although there were 
si群 ficantdifferences among也efour WISC-IV index scores (P < 0.001). The 
PS score (97.1土 15.5)was significantly lower than the VC (107.2土 15.8)and 




MTX dose-dependent manner (107.8, 102ムand96.5 for none，ト19g/m2, and 
higher th阻 20g/m2, respectively; P = 0.05). 
Conclusions 
Japanese childhood cancer survivors, including those in the non-MTX group, 
demonstrated si斜 ficantPS impairment.回gh-doseMTXなea:加巴ntmi位tbe 
associated with neurocog凶tivedeficiencies, particularly in WM. Although 
current trea:加 entsare associatβd with high cure rates, future research and 
interventions are required to improve cognitive function in these patients. 
Keywords: Chemotherapy・ nduced Cognitive Impairment, Childhood Cancer 
Survivors, Cognitive Function, Methotrexat渇
〈
1. Introduction 
Treatment for childhood cancer has improved dramatically in recent years, 
resulting in estimated survival rates higher than 70%.1 Nevertheless, childhood 
cancer survivors, especially those with acute lymphoblastic l巴ukemia(ALL), are 
at risk of late, adverse, neurocog凶tiveeffects, including difficulties with 
attention, visual回motorfunction, processing speed, and working memory. 2・3 Risk 
factors for neurocognitive difficulties include the need for greater intensity of 
cranial radiation伽 rapy(CRT),4・6high-dose metho仕exate倒立）trea加 ent,6・7 
and younger age at diagnosis. 8・ 9 While late neurocognitive adverse e能 ctshave 
been reported in childhood ALL especially for Caucasians, there has been a 
limited focus on other types of childhood cancer and ethnicities. To our 
knowledge, no published reports have examined the effects of treatment on 
《 Japanesepatients with childhood cance日 hisstudy aimed to a悶 SSCO伊 itive
自立ictionin Japanese patients wi也c悩ldhoodcancer whose conditions remained 
stable af主eracute-phase仕ea加ient.
2. Patients and Methods 
2.1. Participants (Table 1) 
｛ 
百世sstudy was pぽtof a larger cross-sectional survey of cognitive function 
following treatment for childhood cancer. Participants were 53 Japanese 
survivors of childhood cancer (mean age, 9.5土3.2[range, 5-16] years; 36 boys 
and 17 girls; ALL, n = 37; acute myeloid leukemia [AML], n = 6; chronic 
myeloid leukemia [C恥1L],n = 1;lymphoma, n = 2;and solid tumors, n = 7), 
recruited企omthe outpatient pedia仕icclinic of Showa U凶Vぽ sityFu igaoka 
Hospital. All pぽticipantscompleted acut巴． has巴仕eatmentand remain巴dstable 
with no history of neurological disease or in ury. None of the patients had 
history of premorbid learning disabilities or other developmental conditions 
before the initial仕ea伽ient.The treatment protocols varied by participant, but 
mostly included systemic corticosteroid, systemic MIX, and/or cytarabine 
administration. Four patients rec巴ivedCRT. Written informed consent was 
obtained企omthe parents, while the children agreed to be interviewed and to 
《 川町gofue制 essment.The蜘 dywas approved by the Ethics Commi蜘 of
Showa University Fujigaoka Hospital, Institutional Review Board (Permit 
Numb巴r:2016037) and was conducted following the provisions of the 
Declaration of Helsinki. 
2ムAssessments
〈
We evaluated performance同basedcognitive function using the Wechsler 
Intelligence Scale for Children-Four也Edition(WISC-IV). Examiners were 
Master-level licensed psychologists qualified and experienced in administering 
the WISC-IV. The WISC-IV provides a full-scale intelligence quotient σSIQ) 
score, as well as four composite Index Scores, and has a s旬ndardizedmean and 
standard deviation (SD) of 100 and 15, respectively. The Index Scores for four 
domains were calculated based on the following subtests; Verbal 
Comprehension (VC; composed of仕ieVocabulary and Similarities subtests ), 
Perceptual Reasoning (PR; Block Design and Matrix Reasoning subtests ), 
Working Memory (WM; Digit Span and Letter-Number Sequencing subtests), 
and Processing Speed (PS; Coding and Symbol Search subtests). All scaled 
scores and Index Scores were derived企omthe raw scores based on the Japanese 
standardization sample data. The WISC-V was not released in Japan at the time 
《 ofdata collection. 
2.3. Data analysis 
All data were analyzed using the Statistical Package for the Social Sciences 
(IBM Corp., Armonk, NY). The box plot revealed no ex出＇meoutliers, and吐ie
WISC-IV FSIQ and al WISC-IV Index Scores were normally distributed. 
Repeated-measures佃 alysisof variance was performed to examine differences 
｛ 
ι 
among吐iecognitive performance domains using the four WISC-IV Index 
Scores as in仕かindividualfactors. Bonferroni post-hoc pairwise comparisons 
were also conducted, while Spearman’s correlations were used to examine the 
relationships between age at diagnosis, counts of intra批 caltherapy (IT), counts 
of high-dose MTX therapy, counts of cyt制 binetherapy, days between complete 
response and testing, and cognitive performance. We divided the patients in 
白reegroups depending on the cumulative h店χdose(none, moderate [1-19 
g/m2], and high [higher than 20 g/m2]) to explore associations between the 
cumulative MTX dose and cognitive function. Finally, we performed subgroup 
analysis of the high, cumulative MTX・dosegroup because previous studies 
indicated that MTX trea加 entcould a能 ctcognitive function. To avoid type I 
error due to multiple comparisons，ぬesignificance level for al analyses was set 
to 0.005 (two・tailed).
3. Results 
The FSIQ was 104.8土15.5,which was within the age-matched average range 
for the general population. Meanwhile, there were significant differences among 
the four WISC-IV Index Scores (F[3, 156] = 7.893, Pく 0.001).Post占oc
analysis revealed the PS score (97 .1士 15.5)to be significantly lower than the 
vc (107.2土 15.8)and PR (105.3土 14.2)scores (eachPく 0.005,Bonferroni 
｛ 
corrected) (Fig. 1). In addition, although age at diagnosis, counts of IT, counts of 
cyt釘abinetherapy, and days between complete response and testing were not 
associated wi也acognitive function domain, the counts of high-dose MTX 
也erapywere significantly correlated with poor WM  performance (r ＝・0.342,p 
= 0.013) (Table 2). Accordingly, we observed a decreasing仕endin WM  
performance as the MTX dose increased; WM  scores for none, moderate, and 
high-dose groups were 107.8, 102ムand96.5, respectively (P = 0.05). Post-hoc 
analysis revealed a sig凶五candylower ＂瓜 Ifscore in the high-MTX group (96.5) 
than in the non-Mτ文 group(107.8; Pく0.05,Boぱbπo凶 corrected)(Fig. 2), 
while the PS score was decreased in al groups including the non-MTX group 
(including patients with AML, CML, and solid tumors）σig. 3). Finally, 
sub旬 groupanalysis in the high MTX group revealed a significantly lower WM  
score (96.5）也組曲eVC (109.6) and PR (106.1) scores (Pく 0.01and P < 0.05, 
《 respectivelぁBonferronicorrected）σig. 4). 
4. Discussion 
The childhood cancer survivors studied herein had intact FSIQ compared with 
the population normative da旬；however,they showed significant PS deficits on 
the group level. Several previous studies found也atalthough general intellectual 
ability in ALL survivors is not affected by chemo也.erapyalone, their PS is 
〈
significantly lower也anthat of comparison peers, 10-12 and this is supported by 
our findings. Generally, central nervous system (CNS）同directedchemotherapy, 
such出 CRTand high幽 doseMTX, is required for ALL and it is well known也at
patients with ALL may have cognitive dysfunction.13 In白ecurrent s飢dy,PS 
was also decreased in the other types of cancer examined. To our knowledge, 
this is the first study investigating the association between cognitive function 
and childhood cancer in patients not receiving CNS-directed chemotherapy. 
Interestingly, our study patients with childhood cancer who did not receive 
high-dose MTX (i.e., those withAML, CML, and solid tumors) also had 
decreased PS. While litle is known about社1eassociation between PS 
impairment and childhood c阻 certreatment other吐ianhigh-dose MTX, 
depression, the effects of long-term hospitalization, and parenting stress could 
play a role. Indeed, there is some evidence from adult cancer survivors that 
ιperc釘 eddepressive symptoms might甜onglyafi ct co伊i帥 performance,14 
while Patel et al.15 reported an association between PS impairment and parenting 
stress. 
In the current studぁanegative correlation was found b巴tweenMTX dose and 
WM  performance. In support of this finding, previous meta-analysis data 
indicated that PS and WM  are significantly impaired in childhood c組 cer
survivors.16 In addition, although some studies found no association between 
〈
MTX dose and neurocognitive outcome,7・ 17 other investigators reported that 
childhood ALL survivors who received high圃 doseintravenous MTX had a 
greater degree ofneurocognitive problems than those administered low-dose 
MTX, 18・20 as indicated by the present study results. All previous studies were 
conducted with Caucasian samples, and our study isせiefirst to confirm也e
S創neresults in an Asian population. 
Rec巴ntlぁacognitive and problem-solving program was implemen匂dfor 
leukemia and brain tumor survivors.21・22 Hardy et al.2 reported good feasibility 
and acceptability of the program with significant increases in WM  and parent 
reports of decreased attention problems following the 12・weekprogram, while 
Moore et al. 23 reported仕iatearly mathematics intervention can pr巴venta decline 
in mathematical ability and cognitive function in patients with childhood ALL. 
Accordingly, we plan to implement an early intervention involving a 
《 compt附 izedcognitive traini 
undergoing chemotherapy. 
Although age at diagnosis, counts of IT, counts of cytarabine社ierapy,and days 
between complete response and testing were not associated with any cognitive 
function domain，仕iecounts of high-dose MTX therapy were significantly 
correlated with poor WM  performance. The patients who received high-dose 
M1χ血erapywere almost al ALL patients and were hospitalized for 
｛ 
《
approximately 1 year, whereas the hospitalization of other patients varied 
between 6 months and 1 year.百ierewas no significant di品 rencein也eage at 
五rstonset with or without high-dose MTX. Based on the above findings, 
long-term hospitalization is considered a confounding factor related to the WM  
decrease in the high-dose MTX administration group. 
In this study, general comparison was difficult because only a small number of 
patients who were hospitalized for approximately 1 year in也econtrol group did 
not receive high-dose MTX. Accordingly, accumulating a larger number of cases 
is necessary in the future because the effects of long-term hospitalization in 
childhood and high・doseM1叉therapyshould also be considered. 
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Figure legends 
Figure 1. Cognitive performance (Wechsler Intelligence Scale for 
Children-Four仕1Edition) of childhood can，回rsurvivors 
〈
IQ: intelligence quotient, VC: verbal comprehension, PR: perceptual reasoning, 
明瓜.f:working memory, PS: process泊gspeed, ANOVA: analysis of variance 
Figure 2.回stogramof total metho回 xate仰TX)dose 
Figure 3. Cognitive perform組問（WechslerIntelligence Scale for 
Children-Four仕iEdition) impairment by metho仕exate(MTX) dose 
IQ: intelligence quotient, VC: verbal comprehension, PR: perceptual reasoning, 
WM: working memory, PS: processing speed, ANOVA: analysis of variance 
Figure 4. Cognitive performance (Wechsler Intelligence Scale for 
Children-Fourth Edition) of childhood cancer survivors in the 
high-metho回 xategroup (> 20 g/m2) 
《 IQ:intelligence quotien VC: verbal com均prel閣e捌 on R:p悦 ep旬alreasonin 













































































































































































































































































































































































































































































F[3, 156] = 7.893, p = 0圃0001(repeated圃 measuresANOVA) 

























































































































































































F[6,60] = 6”954, p < 0.0005 (repeated-measures ANOVA) 
*: p < 0.01，合： p< 0.05 (post-hoc paired t-test) 
戸、
Table 1. Patient characteristics 
Sex: male/female 
Age: median (range) 
Day of examination post hospital 
discharge: median (range) 
ALL/ AML/ CML/ ML/ ST 





9.5 years (5-16 years) 





ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, CML: chronic myeloid 
leukemia, ML: malignant lymphoma, ST: solid tumor, 
Cranial irradiation: cranial irradiation with 12 to 24 grays, 
E王D聞 MTX:high-dose methotrexate (10 g/m2 or 20 g/m2), 
IT: intrathecal therapy (MTX, cytarabine, and steroids) . 
~ ，、
Table2: Relationship between cognitive function and each factor 
.621 .375 .779 .375 .162 
ヘ135 ー.032 問 .157 ヘ198 .054 .113 
.339 .824 .267 .160 .706 .424 
.008 .186 .148 
.958 .186 .543 .294 
ー.171 ー.201 ー.239 .035 ー.063 ー.242
.225 .154 .088 .805 .656 .084 
.113 .120 .008 .076 ー.066 .105 
.422 .391 .955 .590 .638 .453 
FSIQ：白1scale intelligence quotient, VC: verbal comprehension, PR: percep加alreasoning, 
WM: working memory, PS: processing speed , 
IT: intrathecal therapy (MTX, c戸arab恒久 andsteroids) , 
HD-MTX: high-dose methotrexate (10 g/m2 or 20 g/m2), 
AraC: cytarabine is a chemotherapy drug. 

